Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of TMOD3 and/or ADSL in non-small cell carcinoma

A technology in non-small cell lung cancer and samples, applied in the field of disease treatment, can solve the problems of unclear molecular mechanism of non-small cell lung cancer cell regulation, unclear relationship between non-small cell lung cancer, etc., and achieve the effect of enhancing malignant progression

Pending Publication Date: 2022-06-28
ZHENGZHOU YIHE HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Up to now, the relationship between TMOD3 and non-small cell lung cancer is still unclear, and the molecular mechanism of regulation of ferroptosis in non-small cell lung cancer cells is also unclear, which is a major scientific issue

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of TMOD3 and/or ADSL in non-small cell carcinoma
  • Application of TMOD3 and/or ADSL in non-small cell carcinoma
  • Application of TMOD3 and/or ADSL in non-small cell carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1 Expression of TMOD3 in clinical samples of non-small cell lung cancer

[0048] From 2014 to 2016, 118 patients with non-small cell lung cancer (NSCLC) who underwent surgical resection and were pathologically diagnosed in the First Affiliated Hospital of China Medical University were selected. All 118 patients who participated in this pathological correlation analysis did not receive radiotherapy and chemotherapy before surgery. Male patients (N=82) and female patients (N=36), aged between 37 and 77 years. According to the 8th edition of the International Union Against Cancer (UICC) TNM staging system for lung cancer, patients with stage I-IIa (N=61 cases) and patients with stage IIb-IV (N=57 cases). According to the WHO classification system, squamous cell carcinoma (N=58 cases), adenocarcinoma (N=60 cases), moderately to well differentiated (N=67 cases), and poorly differentiated (N=51 cases). Tumor size classification, less than or equal to 3cm cases (N=65...

Embodiment 2

[0053] Example 2 The effect of TMOD3 on the malignant progression phenotype of non-small cell lung cancer

[0054] 1. Expression analysis and interference screening of TMOD3 in non-small cell lung cancer cells

[0055] Non-small cell lung cancer cell lines A549, H1299, H460 and SK-MES-1, normal lung epithelial cell HEB2, and control cell Caco2 were cultured in 25T culture flasks, and then recovered and passaged for 2 generations until the cells were in a stable state.

[0056] Western blot was used to analyze the expression of TMOD3 protein in non-small cell lung cancer cell lines A549, H1299, H460 and SK-MES-1 cells, and HBE2 and Caco2 cells were used as controls, and the experiment was repeated three times. The results showed that the lung adenocarcinoma cell line A549 and the lung squamous cell carcinoma cell line SK-MES-1 showed high expression of TMOD3 ( image 3 A).

[0057] In order to further explore the role of TMOD3 in non-small cell lung cancer, the inventors desi...

Embodiment 3

[0088] Example 3 To study the effect of TMOD3 on ferroptosis in non-small cell lung cancer cells

[0089] Interfering with TMOD3 in A549 and SK-MES-1 cells, and treating the cells with the ferroptosis activator Erastin, the MTT detection kit (Abnova, KA0814) combined with a microplate reader (Biotek microplate reader Epoch, USA) was used for analysis. The results showed that, Erastin alone can inhibit the activity of non-small cell lung cancer cells; and compared with the control interference treatment, interference with TMOD3 can further enhance the inhibitory effect of Erastin on the activity of non-small cell lung cancer cells ( Figure 7 A and B).

[0090] Interfering with TMOD3 in A549 and SK-MES-1 cells, the iron detection kit analysis showed that compared with the control interference treatment, interference with TMOD3 could significantly enhance the content of iron ions in non-small cell lung cancer cells ( Figure 7 C and D).

[0091] The above experiments show that...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of TMOD3 and / or ADSL (Asymmetrical Digital Subscriber Line) in non-small cell carcinoma. The invention discloses application of a reagent for detecting the expression level of TMOD3 and / or ADSL in preparation of a product for detecting non-small cell lung cancer. The invention further discloses application of the ADSL accelerant in preparation of a medicine for treating non-small cell lung cancer. The invention reveals that the new NSCLC oncogene TMOD3 and cancer suppressor gene ADSL play an important role in malignant progression and ferroptosis of non-small cell lung cancer and a potential molecular mechanism of the NSCLC oncogene TMOD3 and the cancer suppressor gene ADSL, a basis can be provided for diagnosis, treatment and prognosis of NSCLC, and a new research direction and a theoretical basis are provided for precise treatment.

Description

technical field [0001] The present invention relates to the field of disease treatment. Specifically, the present invention relates to the use of TMOD3 or ADSL in non-small cell carcinoma. Background technique [0002] Non-small cell lung cancer (NSCLC) is one of the malignant tumors with the highest morbidity and mortality in my country and even in the world, which seriously endangers human health and is an urgent problem to be solved. Lung cancer is still one of the biggest threats to human life and health, among which non-small cell lung cancer accounts for 80%-85%. In recent years, great progress has been made in the treatment of non-small cell lung cancer, including targeted therapy, chemotherapy, surgery, and radiotherapy. However, there are still many serious problems to be solved, mainly including: drug sensitivity caused by heterogeneity, recurrence and poor prognosis caused by drug resistance and metastasis, and the lack of targeted and precise therapeutic target...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574A61K45/00A61P35/00
CPCC12Q1/6886G01N33/57423A61K45/00A61P35/00C12Q2600/158C12Q2600/136C12Q2600/118
Inventor 赵智姜丽红冯亚娟邢阳席乐峰李凤营高斐佩王利勤张德臣孙建平杜正仙杨广英
Owner ZHENGZHOU YIHE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com